4-氯-1H-吡咯并[2,3-b]吡啶-2(3H)-酮 | 346599-62-0

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 4-氯-1H-吡咯并[2,3-b]吡啶-2(3H)-酮
• 中文别名: 4-氯-1H-吡咯[2,3-B]吡啶-2(3H)-ONE；4-氯-1H-吡咯并[2,3-B]吡啶-2(3H)-酮；4-氯-7-氮杂吲哚-2-酮；4-氯-7-氮杂-吲哚-2-酮
• 英文名称: 4-chloro-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one
• 英文别名: 4-chloro-1H-pyrrolo[2,3-b]pyridin-2(3H)-one；4-chloro-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one；4-chloro-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one；4-chloro-1,3-dihydropyrrolo[2,3-b]pyridin-2-one
• CAS: 346599-62-0
• 化学式: C₇H₅ClN₂O
• mdl: MFCD11518939
• 分子量: 168.583
• InChiKey: MUJHLWISGAWFPZ-UHFFFAOYSA-N

物化性质

• 沸点：
  373.0±42.0 °C(Predicted)
• 密度：
  1.450±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Chloro-1h-pyrrolo[2,3-b]pyridin-2(3h)-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Chloro-1h-pyrrolo[2,3-b]pyridin-2(3h)-one
CAS number: 346599-62-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5ClN2O
Molecular weight: 168.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

4-氯-1H-吡咯并[2,3-b]吡啶-2(3H)-酮是一种酮类衍生物，可用作医药中间体。

制备

将7-氮杂吲哚溶解于10 mL二氯甲烷中，冷却至0℃后，缓慢滴加4.2 mL冰乙酸，并搅拌20分钟。接着，分批加入5.6 g（37 mmol）三氯氧磷的20 mL二氯甲烷溶液，继续在0℃下反应2小时。通过薄层色谱跟踪检测反应进程，直至未见反应物为止。使用甲醇作为展开剂进行TLC检测，产物Rf值为0.57。

反应结束后，向体系中加入饱和亚硫酸钠水溶液至淀粉KI试纸不变蓝。浓缩二氯甲烷后，再加入20 mL水，并在0℃下用NaOH调节pH值至＞13。然后将混合物溶剂旋干，有机相用二氯甲烷溶解，用水洗两次，有机相经无水硫酸钠干燥处理。最后通过硅胶柱层析色谱分离纯化产物，并真空干燥后得到4-氯-1H-吡咯并[2,3-b]吡啶-2(3H)-酮。

反应信息

• 作为反应物：
  描述：

  4-氯-1H-吡咯并[2,3-b]吡啶-2(3H)-酮 在 三氟乙酸 作用下， 以 N-甲基吡咯烷酮 、 二氯甲烷 为溶剂， 反应 1.75h， 生成 4-(4-amino-piperidin-1-yl)-1H-pyrrolo[2,3-b]pyridine-2,3-dione
  参考文献：
  名称：

  WO2007/125320

  摘要：

  公开号：
• 作为产物：
  描述：

  7-氮杂吲哚 在 palladium 10% on activated carbon pyridinium hydrobromide perbromide 、 水 、 potassium carbonate 、 甲基磺酰氯 作用下， 以 乙醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成 4-氯-1H-吡咯并[2,3-b]吡啶-2(3H)-酮
  参考文献：
  名称：

  WO2007/125320

  摘要：

  公开号：
• 作为试剂：
  描述：

  3,3-dibromo-4-chloro-1H-pyrrolo[2,3-b]pyridin-2(3H)-one 、 溶剂黄146 、 甲醇 、 乙酸乙酯 在 锌 4-氯-1H-吡咯并[2,3-b]吡啶-2(3H)-酮 、 乙酸乙酯 、 Brine 、 magnesium sulfate 、 silica gel 、 二氯甲烷 作用下， 以 Brine 为溶剂， 反应 3.0h， 以White cotton-like solid, 4-chloro-1H-pyrrolo[2,3-b]pyridin-2(3H)-one was obtained的产率得到4-氯-1H-吡咯并[2,3-b]吡啶-2(3H)-酮
  参考文献：
  名称：

  Aurora Kinase Modulators and Method of Use

  摘要：

  本发明涉及具有一般式I的化合物，其中定义了A1、A2、C1、C2、D、L1、L2、Z和R3、R4、R6、R7和R8，这些化合物能够调节极化激酶蛋白活性，从而影响与极化激酶蛋白活性相关的各种疾病状态和情况。例如，这些化合物能够影响细胞周期和细胞增殖的过程，以治疗癌症和与癌症相关的疾病。本发明还包括制备本发明化合物的药物组合物、合成中间体和治疗与极化激酶活性相关疾病的方法。

  公开号：

  US20110263530A1

文献信息

• [EN] BIARYL KINASE INHIBITORS<br/>[FR] INHIBITEURS BIARYLES DE KINASES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017059080A1

  公开（公告）日：2017-04-06

  The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAKl (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.

  本公开涉及公式（I）的联苯化合物，可以抑制AAK1（适配器相关激酶1），包括这种化合物的组合物以及它们用于治疗疼痛、阿尔茨海默病、帕金森病和精神分裂症等的用途。
• [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION
  申请人：INTEGRAL BIOSCIENCES PVT LTD

  公开号：WO2020012357A1

  公开（公告）日：2020-01-16

  The present invention discloses compounds useful in treatment of conditions associated with excessive activity of transforming growth factor beta (TGF-β), particularly type 1 or activin-like kinase 5 (ALK 5). Specifically the present invention discloses compound of formula (I) which exhibit inhibitory activity against ALK 5. Method of treating conditions associated with excessive activity (ALK 5) with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.

  本发明揭示了在治疗与转化生长因子β（TGF-β）过度活性相关的疾病中有用的化合物，特别是针对类型1或类活化激酶5（ALK 5）。具体来说，本发明揭示了具有对ALK 5具有抑制活性的化合物的结构式（I）。还公开了使用这种化合物治疗与过度活性（ALK 5）相关的疾病的方法。此外，还公开了这些化合物的用途、制药组合物和试剂盒。
• [EN] NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS<br/>[FR] DÉRIVÉS INÉDITS FUSIONNÉS DE PYRIDINE POUVANT ÊTRE UTILISÉS EN TANT QU'INHIBITEURS DE LA TYROSINE KINASE C-MET
  申请人：ZHEJIANG BETA PHARMA INC

  公开号：WO2014000713A1

  公开（公告）日：2014-01-03

  This invention relates to novel fused quinazoline derivatives of Formula I as c-Met inhibitors, their synthesis and uses for treating c-Met mediated disorders.

  这项发明涉及一种新颖的融合喹唑啉衍生物，其化学式为I，作为c-Met抑制剂，以及它们的合成和用于治疗c-Met介导的疾病的用途。
• 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
  申请人：——

  公开号：US20020183319A1

  公开（公告）日：2002-12-05

  This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Particular 4-substituted 7-aza-indolin-2-ones disclosed herein are of Formula 1 1 and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R 1 , R 2 , R 3 , R 4 , X, Y, and Z are defined herein. The invention fuirther relates to pharmaceutical compositions and dosage forms comprising compounds of Formula 1 and to methods of their use for the treatment and/or prevention of diseases such as, but not limited to, cancer.

  该发明涉及4-取代的7-氮杂吲哚-2-酮及其作为蛋白激酶抑制剂的用途。本文披露的特定4-取代的7-氮杂吲哚-2-酮属于第11式和其药学上可接受的盐、溶剂合物、包合物和前药，其中R1、R2、R3、R4、X、Y和Z在此定义。该发明还涉及包含第1式化合物的药物组合物和剂型，以及其用于治疗和/或预防癌症等疾病的方法。
• Aurora kinase modulators and method of use
  申请人：Cee J. Victor

  公开号：US20070185111A1

  公开（公告）日：2007-08-09

  The present invention relates to chemical compounds having a general formula I wherein A 1 , A 2 , C 1 , C 2 , D, L 1 , L 2 , Z and R 1 - are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式I的化合物，其中A1、A2、C1、C2、D、L1、L2、Z和R1-在此定义，并且具有调节各种蛋白激酶受体酶的能力，从而影响与这些激酶活动相关的各种疾病状态和病况。例如，这些化合物能够调节枢纽激酶，从而影响细胞周期和细胞增殖过程，用于治疗癌症和癌症相关疾病。该发明还包括含有这些化合物的药物组合物，以及治疗与枢纽激酶活性相关的疾病状态的方法。